Rare diseases
Investigational molecules
Locations
459 conditions with trials, the busiest first
1 397 trials across Europe, recruiting first
Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients
BelgiumEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
AustriaAustriaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaSafety Study of NB-4746 with Riluzole and Placebo in Adults with Amyotrophic Lateral Sclerosis (ALS)
ItalyPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
AustriaA study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
CzechiaA study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis
BelgiumPhase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury
DenmarkA study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis
PolandA study to evaluate the effectiveness and safety of usnoflast in adults with Amyotrophic Lateral Sclerosis (ALS)
BelgiumThe therapies tested most often in Nervous system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
